MK-677 (Ibutamoren) 2026: What It Is, Where It Sits, and Why We Don't Link to Vendors
MK-677 — also called ibutamoren — is technically not a peptide. It's a small-molecule, orally bioavailable growth-hormone secretagogue that activates the ghrelin/GHS receptor to stimulate pulsatile GH release. Despite the molecular distinction, MK-677 is universally grouped with the peptide secretagogue class because it produces a similar clinical effect through a similar receptor pathway.
MK-677 is on the October 2024 PCAC docket for FDA review — its regulatory status is actively in flux. As of this page being published, MK-677 is not FDA-approved, not currently compounded under 503A authority, and not legitimately available through licensed clinical channels in the US.
We include MK-677 on this site because consumer search interest is significant and patients researching GH secretagogues need accurate information about why it doesn't have a clean clinical path. We do NOT link to research-chemical vendors, regardless of disclaimers. If you are considering MK-677 therapeutically, the appropriate path is a clinician conversation about whether an injectable GHRH/GHRP combo (sermorelin + ipamorelin, CJC-1295 + ipamorelin) is right for you instead.
- 10 programs ranked
- Editor-reviewed
- Reader-verified
- Updated weekly
What's actually available: MK-677 (Ibutamoren) samples in 2026
Three paths for people typing “mk-677 (ibutamoren)samples” — what they actually mean, typical cost, and who each path fits.
| Path | What it actually is | Typical cost | Best for |
|---|---|---|---|
| Clinical alternative: injectable GHRH + GHRP | Sermorelin + ipamorelin, or CJC-1295 + ipamorelin via specialty peptide clinic. | $99-450 / month depending on path | Patients seeking the GH secretagogue clinical effect through a legitimate Rx path |
| Clinical alternative: tesamorelin (Egrifta) | FDA-approved GHRH analog with strong VAT-reduction data. | $2,500-5,000 / month off-label cash | Patients with budget for the FDA-approved option targeting visceral fat |
| MK-677 itself: no recommended path | We do not recommend or link to any source for MK-677 acquisition. | N/A | N/A — see clinical alternatives above |
How MK-677 (Ibutamoren) samples actually work
Why MK-677 is grouped with peptides despite being a small molecule
MK-677 binds the ghrelin/growth-hormone-secretagogue receptor (GHS-R), the same receptor that ghrelin and the GHRP class of peptides act on. The downstream signaling — pituitary GH release pulse — is similar to GHRP-class peptides (ipamorelin, GHRP-2, GHRP-6). Patients searching for GH secretagogues encounter both the peptide secretagogues and MK-677 as functionally similar options, which is why we cover MK-677 here despite the technical molecular distinction.
The sustained-elevation pattern
Unlike injectable secretagogues (which produce discrete pulses), oral MK-677 produces sustained 24-hour elevation in GH and IGF-1. The convenience appeal is obvious — daily oral dose vs. injection. The clinical tradeoff is the same as CJC-1295 with DAC: sustained elevation departs from natural pulsatile physiology, can produce more water retention and insulin resistance, and may have different long-term implications for the GH/IGF-1 axis than pulse-pattern dosing.
Why we don't link to MK-677 vendors
MK-677 is currently sold by research-chemical vendors with 'Research Use Only' disclaimers. The April 2026 FDA enforcement action against 7 RUO peptide vendors made it clear that RUO labeling does not protect against drug-misbranding charges when the marketing context implies human use. We treat MK-677 the same way we treat BPC-157 and TB-500 — present the molecule for educational context, do not link to vendors, route patients toward legitimate clinical alternatives.
MK-677 is the GH secretagogue patients want because it's oral and convenient. It's also the one with the worst US regulatory posture and the highest exposure if something goes wrong. We list it for the search traffic; we do not link to vendors.
MK-677 (Ibutamoren) cost in 2026: every legitimate price path
What you'll actually pay depends on insurance, the path you take, and whether you stay on the brand-name drug. Here's the real money:
| Path | First month | Ongoing | Notes |
|---|---|---|---|
| Sermorelin + ipamorelin (telehealth) | $99-149 | $99-249 / mo | Recommended clinical alternative for the GH secretagogue effect via legitimate Rx path. |
| CJC-1295 + ipamorelin (telehealth or clinic) | $129-199 | $129-279 / mo | Alternative GHRH + GHRP combo with weekly CJC dosing. |
| Tesamorelin (FDA-approved) | $2,500-5,500 | $2,500-5,000 / mo | FDA-approved GHRH analog if visceral fat reduction is the goal. |
What to expect on MK-677 (Ibutamoren): your first weeks
We do not provide MK-677 acquisition guidance.
If you are considering a GH secretagogue clinically, the appropriate next step is a consultation with a peptide-friendly clinician.
Marek Health, Defy Medical, Eden, Hone, AgelessRx, and GobyMeds (referral network) all support this conversation.
Clinical evidence behind MK-677 (Ibutamoren)
MK-677's effect on GH and IGF-1 elevation is well-characterized in published studies, primarily from Merck's original development program. Long-term outcome data is limited; commercial development was abandoned for reasons including elevated fasting glucose and water retention seen in trials. Current research interest is largely from the longevity and athletic-performance spaces rather than primary clinical development.
MK-677 (Ibutamoren)side effects & who shouldn't take it
This is not medical advice. Discuss every medication decision with a licensed clinician who knows your full medical history.
Common side effects
- •Increased fasting glucose / insulin resistance (common in trials)
- •Water retention and edema
- •Increased appetite (ghrelin/GHS receptor activity)
- •Elevated cortisol and prolactin (less than older GHRPs but still measurable)
- •Lethargy and decreased exercise tolerance in some patients
Who shouldn't take MK-677 (Ibutamoren)
- •Patients with active malignancy
- •Patients with significant insulin resistance or diabetes
- •Patients with congestive heart failure (water retention concerns)
- •Pregnancy or breastfeeding
- •Patients seeking a legitimate Rx path — choose the injectable GHRH + GHRP alternative instead
Eligibility for MK-677 (Ibutamoren)
- •We do not provide eligibility guidance for MK-677 acquisition.
- •For the clinical GH secretagogue effect, the eligibility framework is the same as the injectable GHRH + GHRP class.
- •See the sermorelin or ipamorelin pages for eligibility criteria for clinical alternatives.
MK-677 (Ibutamoren) samples: frequently asked
Why don't you link to MK-677 vendors?
MK-677 is currently sold only by research-chemical vendors with 'Research Use Only' disclaimers. The April 2026 FDA enforcement action against 7 RUO peptide vendors clarified that RUO labeling does not protect against drug-misbranding charges when marketing context implies human use. Linking to those vendors creates downstream regulatory exposure for our readers and for us. We don't do it.
Is MK-677 going to become FDA-approved?
Unknown. Merck abandoned commercial development decades ago. MK-677 is on the October 2024 PCAC docket for FDA review which addresses 503A compounding eligibility, not new-drug approval. A new-drug-approval pathway for MK-677 would require a sponsor and a phase-3 trial program — neither is currently underway.
What's the closest clinical alternative to MK-677?
Injectable GHRH + GHRP combination (sermorelin + ipamorelin, or CJC-1295 + ipamorelin) produces a similar clinical effect via legitimate Rx path. Daily injection vs. daily oral is the convenience tradeoff. Pulse-pattern dosing is generally considered closer to natural physiology than MK-677's sustained elevation.
Why is MK-677 included on this site if you don't link to vendors?
Two reasons. First, search-traffic and consumer education — patients researching GH secretagogues encounter MK-677 prominently and need accurate information about its US regulatory posture. Second, channeling — patients who land on this page can be redirected to the legitimate clinical alternative (injectable GHRH + GHRP) before they make decisions based on vendor marketing.
Is MK-677 a SARM?
No. MK-677 is sometimes grouped with SARMs in vendor marketing because both classes include orally bioavailable performance-research compounds, but mechanistically they're unrelated. SARMs are selective androgen receptor modulators acting on androgen receptors; MK-677 is a ghrelin/GHS receptor agonist. The grouping is marketing convention, not pharmacology.